Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.

Abstract excerpt

Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood-Brain Barrier
• Share to Brain Neoplasms